Science Explorer Back to mapMap
Discussion
Topic · Immunology

Inflammation biomarkers and pathways

Inflammation biomarkers and pathways is a research topic within Immunology. Science Explorer counts 8.4k research works in it since 1959. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the role of triggering receptor expressed on myeloid cells-1 (TREM-1) and endocan in inflammatory responses, sepsis, and various inflammatory diseases. It investigates their impact on immune cells such as macrophages and neutrophils, as well as their potential as diagnostic markers for conditions like pneumonia and septic shock.

  • TREM-1
  • Endocan
  • Inflammation
  • Sepsis
  • Macrophages
  • Neutrophils
  • Endothelial Cells
  • Immune Response
  • Diagnostic Marker
  • Inflammatory Diseases
Research works
8.4k
fractional, since 1959
In the world top 10%
846
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+35%
the tick is no change
Largest producer
China
57% of the 10 largest, 2022-now
Inflammation biomarkers and pathways

Which countries lead Inflammation biomarkers and pathways research?

By volume, China and the United States publish the most (1.3k and 408 works in 2022-now).

By volume, 2022-now

  1. 1 China 1.3k works
  2. 2 United States 408 works
  3. 3 Türkiye 143 works
  4. 4 India 73 works
  5. 5 United Kingdom 71 works
  6. 6 Germany 64 works
  7. 7 Japan 60 works
  8. 8 Italy 49 works
  9. 9 Indonesia 46 works
  10. 10 Egypt 42 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 57.0%United States: 18.3%Türkiye: 6.4%India: 3.3%6 others listed: 14.9%57%largest
China1,269 · 57.0%United States408 · 18.3%Türkiye143 · 6.4%India73 · 3.3%6 others listed332 · 14.9%

Shares of the rows listed above, not of the whole node.

Which institutions lead Inflammation biomarkers and pathways research?

By volume in 2022-now, Capital Medical University publishes the most Inflammation biomarkers and pathways research, followed by Central South University and Shanghai Jiao Tong University.

By volume, 2022-now

  1. 1 Capital Medical UniversityChina 38 works
  2. 2 Central South UniversityChina 31 works
  3. 3 Shanghai Jiao Tong UniversityChina 29 works
  4. 4 Sun Yat-sen UniversityChina 26 works
  5. 5 Nanjing Medical UniversityChina 26 works
  6. 6 Zhejiang UniversityChina 22 works
  7. 7 Huazhong University of Science and TechnologyChina 21 works
  8. 8 Wenzhou Medical UniversityChina 19 works
  9. 9 Sichuan UniversityChina 19 works
  10. 10 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 18 works

Who are the leading researchers in Inflammation biomarkers and pathways?

The most-cited researchers publishing on Inflammation biomarkers and pathways include George Davey Smith, Shizuo Akira and Jun Wang.

  1. 1 George Davey Smith United Kingdom 435k citations
  2. 2 Shizuo Akira Japan 342k citations
  3. 3 Jun Wang China 340k citations
  4. 4 Gregory Y.H. Lip United Kingdom 311k citations
  5. 5 John Q. Trojanowski United States 286k citations
  6. 6 Jean‐Louis Vincent Belgium 262k citations
  7. 7 Piotr P. Ponikowski Poland 253k citations
  8. 8 Cornelia M. van Duijn Netherlands 250k citations
  9. 9 Kaj Blennow Sweden 247k citations
  10. 10 André Gerardus Uitterlinden Netherlands 246k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Inflammation biomarkers and pathways?

The most cited paper in Inflammation biomarkers and pathways is "Myeloid-derived suppressor cells as regulators of the immune system" (Dmitry I. Gabrilovich, Srinivas Nagaraj, 2009), with 6,796 citations. Next come "The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases" (3,182) and "TREM2 Variants in Alzheimer's Disease" (3,108).

Most cited papers
#PaperReleasedCitations
1 Myeloid-derived suppressor cells as regulators of the immune system Dmitry I. Gabrilovich, Srinivas Nagaraj · Nature reviews. Immunology ReviewOpen access 7 Feb 2009 6,796
2 The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases Susanne Krasemann et al. · Immunity Open access Sep 2017 3,182
3 TREM2 Variants in Alzheimer's Disease Rita João Guerreiro et al. · New England Journal of Medicine Open access 14 Nov 2012 3,108
4 Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards Vincenzo Bronte, Sven Brandau, Shu‐Hsia Chen et al. · Nature Communications Open access 6 Jul 2016 2,806
5 The immunopathogenesis of sepsis Jonathan B. Cohen · Nature Dec 2002 2,766
All 100 most cited papers, with filters and sorting

Where is Inflammation biomarkers and pathways research done?

The largest centres of Inflammation biomarkers and pathways research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Wenzhou.

Largest cities, 2022-now

  1. 1 BeijingChina 128 works
  2. 2 ShanghaiChina 84 works
  3. 3 GuangzhouChina 79 works
  4. 4 NanjingChina 52 works
  5. 5 ChangshaChina 49 works
  6. 6 HangzhouChina 45 works
  7. 7 WuhanChina 44 works
  8. 8 ChengduChina 35 works
  9. 9 ChongqingChina 34 works
  10. 10 IstanbulTürkiye 34 works

Where it is the local speciality

  1. WenzhouCN · 20.1 works8.3×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Inflammation biomarkers and pathways than the world average.

See Inflammation biomarkers and pathways on the map

Where is the best place to study Inflammation biomarkers and pathways?

Among universities, judged by research, Central South University, Washington University in St. Louis and Capital Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 16.9%fractional works in this field (log) →share of work in the world top 10% →Washington Universit…Huazhong University …Central South Univer…Capital Medical Univ…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Central South UniversityChina 64.822.7%6.5×31 +96.0%
2Washington University in St. LouisUnited States 64.138.7%5.8×10 +29.5%
3Capital Medical UniversityChina 57.910.1%14.6×38 +82.4%
4Huazhong University of Science and TechnologyChina 54.723.9%4.8×21 +68.7%
5Sun Yat-sen UniversityChina 53.113.9%5.2×26 +24.9%
6Shanghai Jiao Tong UniversityChina 52.813.0%4.2×29 +23.2%
7Nanjing Medical UniversityChina 48.811.0%11.9×26 +7.4%
8Wenzhou Medical UniversityChina 46.911.3%15.8×19 +36.2%
9Zhejiang UniversityChina 46.89.8%3.4×22 +33.8%
10Southern Medical UniversityChina 46.614.6%11.4×17 +70.5%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Inflammation biomarkers and pathways, country by country

Is Inflammation biomarkers and pathways research growing?

Output in 2022-2025 was 35% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Inflammation biomarkers and pathways.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Inflammation biomarkers and pathways as a percentage of every work published that year, 0.0089% in 2024.

still counting0.0050%0.010%0.015%Inflammation biomarkers and pathways0.013% in 202519801990200020102020

Fractional works of Inflammation biomarkers and pathways over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Inflammation biomarkers and pathways10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Inflammation biomarkers and pathways. Posts are plain text and can be reported.